________________________________________________________________________________________________________________________________

(C) Alessandra Benedetti 2012 - José Graziano da Silva / B2Bioworld

FAO: Major shifts expected in operations

03-01-2012. José Graziano da Silva, new Director-General details his plans and unveils the approach to implementation. He is striving for sensible changes in operations. A focus is on agricultural production of regional crops. FAO's revised policy will have significant repercussions in the organisation, for its present partners, and the programmatic fight against hunger. Opportunities and constraints. A report by João F. Santos Pessoa and Wolf G Kroner on the inaugural press conference of FAO’s incoming Director-General at Rome.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 4 pages

Full Company License enquire here

Back to section

Related Editorial Articles

Teeth to the Convention on Biological Diversity
Christian Wichard, Deputy Director General of WIPO on its role in enforcing compliance with access and benefit sharing requirements

The Global Dimension of EU Health and Food Policies
Paola Testori-Coggi, former Director-General for Health and Consumers, European Commission

Plant Genetic Engineering: ”It’s not as simple as Yes or No !”
Nobel Prize winner Prof. Christiane Nüsslein-Volhard Warns of GMO-populism. Exclusive interview for readers of B2Bioworld

Brazil needs to improve greater integrity in public service

Plants are Nature’s Best Chemists
Industrial plant biotechnology is an interdisciplinary toolbox which combines the best approaches in conventional as well as organic agriculture, in industrial production, plant molecular biology, and engineering

TALEs, Zinc Fingers, or Meganucleases
A Practice View from Crop Research and Breeding by Johan Botterman, Head of Product Research Bayer CropScience

AstraZeneca and MedImmune Trigger Public Investments into Brazil's Translational Healthcare